A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.
A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
The effect of MYD88 and CXCR4 mutations on therapy response among patients with treatment-naïve Waldenström macroglobulinemia requires further investigation.
A better understanding of current practices may lead to improved, standardized care, as well as better use of health care resources in Waldenström macroglobulinemia.
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.
Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.
Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator’s choice chemotherapy of CHOP, CVP, or bendamustine.
Moffitt Cancer Center investigators believe allo-HCT may actually be “curative” for patients with a certain type of lymphoma.
The introduction of rituximab has greatly improved outcomes among patients with follicular lymphoma, but its impact on the risk of transformation and post-transformation are unclear.
The effectiveness of ibrutinib in the frontline setting has not been definitively established.
While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.
Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.
Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.
Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.
The impact of dose-intensity reduction in Waldenstrom macroglobulinemia has not been explored.
Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.
Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.
A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
Rituximab, gemcitabine, plus oxaliplatin has shown high efficacy with low toxicity among elderly patients with relapsed/refractory diffuse large b-cell lymphoma in previous studies.